| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10912186 | Lung Cancer | 2005 | 6 Pages |
Abstract
The advised dose for future studies in these patients is 200Â mg/day. At this dose level, the toxicity is mild and routine monitoring of neurological toxicity (SNAP test) can be omitted. The percentage of patients seen with prolonged disease stabilization upon thalidomide treatment warrants phase III studies in MPM.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul Baas, Willem Boogerd, Otilia Dalesio, Annebeth Haringhuizen, Frank Custers, Nico van Zandwijk,